Molecular Partners AG
Other OTCTotal Valuation
Molecular Partners AG carries a market capitalization of 142.54M, placing it among publicly traded companies globally. Its enterprise value stands at -8.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 142.54M |
| Enterprise Value | -8.09M |
Share Statistics
Molecular Partners AG currently has 37.51M shares outstanding.
| Shares Outstanding | 37.51M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.21 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | -1.40 |
| P/OCF Ratio | -1.39 |
Enterprise Valuation
| EV / Sales | 18.42 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Molecular Partners AG maintains a current ratio of 9.42, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.89, indicating elevated leverage, while an interest coverage ratio of -2,532.35 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.42 |
| Quick Ratio | 9.21 |
| Debt / Equity | 4.89 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -2,532.35 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -50.73 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 4,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Molecular Partners AG's stock has declined approximately -9.95261% over the past 52 weeks. The 50-day moving average sits at 3.80, while the 200-day moving average is 3.22.
| Beta (5Y) | N/A |
| 52-Week Price Change | -9.95261% |
| 50-Day Moving Average | 3.80 |
| 200-Day Moving Average | 3.22 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -50.65M, while operating income came in at -52.74M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -52.74M |
| Pretax Income | -58.02M |
| Net Income | -58.03M |
| EBITDA | -50.65M |
| EBIT | -52.74M |
| Earnings Per Share (EPS) | -1.55 |
Balance Sheet
Molecular Partners AG holds 78.77M in cash and equivalents against 3.34M in total debt, resulting in a net debt position of -64.25M. Total book value stands at -320.59M, with working capital of 74.13M providing operational flexibility.
| Cash & Cash Equivalents | 78.77M |
| Total Debt | 3.34M |
| Net Debt | -64.25M |
| Equity (Book Value) | -320.59M |
| Book Value Per Share | -8.56 |
| Working Capital | 74.13M |
Cash Flow
Molecular Partners AG produced -48.42M in operating cash flow over the past twelve months. After subtracting -266,000.00 in capital expenditures, free cash flow totaled -48.69M - equivalent to -1.30 per share.
| Operating Cash Flow | -48.42M |
| Capital Expenditures | -266,000.00 |
| Free Cash Flow | -48.69M |
| FCF Per Share | -1.30 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 1.69 |
| FCF Yield | -71.51 |
Scores
Molecular Partners AG posts an Altman Z-Score of -4.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.05 |